Browsing Tag
metabolic dysfunction-associated steatohepatitis
3 posts
Madrigal Pharmaceuticals adds Phase 2 DGAT-2 inhibitor ervogastat to MASH pipeline under global licensing agreement
Find out how Madrigal Pharmaceuticals is expanding its MASH strategy with a global license for ervogastat, a Phase 2 DGAT-2 inhibitor.
MetaVia unveils breakthrough Phase 2a data showing vanoglipel improves liver markers and glucose control in MASH patients
Find out how MetaVia’s vanoglipel improved liver enzymes and glucose control in its Phase 2a MASH trial — see why investors are taking notice today.
Eli Lilly’s tirzepatide shows promising results in MASH treatment study
Eli Lilly and Company (NYSE: LLY) revealed compelling outcomes from the SYNERGY-NASH study, showcasing significant efficacy of tirzepatide…